Find Clinical Trials

Inclusion Criteria: 1. Adults aged 18-64 years with T2DM, BMI 25-35 kg/m2 2. On stable Semaglutide 1 mg weekly and for at least 3 months 3. HbA1c \<8%, eGFR≥60 ml/minute 4. For women: either non-childbearing potential or agreement to use acceptable contraception Exclusion Criteria: 1. Participation in another investigational drug clinical study within 3 months 2. History of cardiovascular or cerebrovascular disease 3. Neuropathy or retinopathy or macular edema necessitating medical treatment 4. Type 1 diabetes 5. Unstable weight (\> 5% change in the last 3 months) 6. Current use of insulin and /or sulfonylureas and/or glinides 7. Known contraindications to Semaglutide (per FDA-approved Semaglutide label) 8. Recent immunosuppressive therapy (within 90 days) or chemotherapy for malignancy within 5 years 9. Moderate or severe hepatic impairment, (ALT or AST\> 2 x upper limit of normal (ULN) 10. Severe hypertriglyceridemia (triglycerides \>500 mg/dl) 11. Pregnant or breast feeding 12. Any condition that may increase risk or interfere with study participation (per Investigator judgement)

Inclusion Criteria: * Primary open-angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma with an indication for glaucoma surgery (defined as uncontrolled intraocular pressure or worsening of visual fields, despite maximum tolerated medical therapy) and an open iridocorneal angle (trabeculum visible on gonioscopy, Shaffer classification grade 3-4) * Healthy, mobile conjunctiva (without scarring or adhesions). * The indication for glaucoma surgery is defined as uncontrolled IOP or worsening of visual fields despite maximum tolerated medical therapy, and with either a previous failure of trabeculectomy or a risk of failure. * Maximum tolerated medical therapy: 3 or more classes of ocular hypotensive treatment, or fewer if there is an allergy or intolerance to the treatment. Visual field defects must be more severe than -3 dB in mean deviation. Exclusion Criteria: * severe systemic pathologies * other ophtalmic pathologies (except cataract) * previous intraocular surgery (except cataract) * neovascular glaucoma or iris neovascularization * pachymetry \< 490µm or \> 620µm * contraindication to PRESERFLO Microshunt

Inclusion Criteria: * Can safely receive TMS and study drugs * Stable medication regimen for one month prior to study participation, and for the duration of the study * Not currently receiving TMS, ECT, or ketamine * No active safety concerns related to suicidality * Moderate to severe Major Depressive Disorder as indicated by the Patient Health Questionnaire or Quick Inventory of Depressive Symptomatology Exclusion Criteria: * History of seizures or epilepsy * History of intracranial pathology or lesions from any etiology * History of traumatic brain injury including prolonged loss of consciousness more than 15 min * Signs of increased intracranial pressure * Any major neurological conditions (ex: recent stroke, tumor, neurodegenerative disorders, etc.) * Major medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) * Severe migraines that may result in treatment intolerance. * Inability to tolerate MRI. * Pregnancy * Known allergic reaction to d-cycloserine, baclofen, memantine, or lorazepam

Inclusion Criteria: * Women aged between 18 and 45 years * Women who have undergone cesarean section * Within the first 24 hours postpartum * Able to communicate in Turkish * Having a healthy singleton newborn * Willing to participate and provide informed consent Exclusion Criteria: * History of psychiatric disorders * Presence of severe maternal complications * Newborn requiring intensive care unit admission * Women with communication difficulties * Participation in another intervention study

Inclusion Criteria: 1. Individual aged between 18 and 65 2. Currently serving as a formal (i.e., designated as a legal caretaker \[e.g., legally authorized representative of medical care\]) or informal (e.g., providing caretaking duties but not formally designated by a legal body) caretaker to a Veteran. 3. Mild to moderate depressive symptoms, as determined by the PHQ-9 (score of 5-14) 4. Reliable access to a computer/tablet and the internet 5. Ability to provide informed consent \- Exclusion Criteria: 1\. PHQ-9 score below 4 or 15 and above 2. Active alcohol or substance use disorder, excluding Cannabis dependence, as determined by screening or electronic medical record 3. Identification of active psychosis or bipolar disorder, as determined via screening or electronic medical record 4. Severe cognitive impairment precluding the ability to provide informed consent \-

Inclusion Criteria: * Self-identified Hispanic Ethnicity * Spanish-speaking * Type 2 diabetes diagnosis, .g., physician documented diagnosis, HbA1c at least 6.5, treatment with a glucose-lowering agent Exclusion Criteria: * Condition known to alter HbA1c levels, e.g., recent transfusion, systemic steroids * Severe mental illness or cognitive impairment that would preclude participation in group activities * Pregnancy during the intervention period * Type 1 diabetes mellitus

Inclusion Criteria: * 18 years and older who reside in the 5 boroughs of NYC, * whom speak English or Spanish, * have a known diagnosis of hypertension, and * have uncontrolled hypertension, defined as two measures of systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg obtained during their ED visit. Exclusion Criteria: * Patients who are unable to consent, * pregnant patients, * patients with a history of end stage renal disease, a history of heart failure or a BMI of greater than 50.

Inclusion Criteria: * Patients with T2DM 1. Who have been diagnosed with T2DM and meet the diagnostic criteria defined by the Chinese Guideline for the Prevention and Treatment of Diabetes (2024 Edition); 2. Aged ≥18 years; 3. Who volunteer to participate in this study. Healthcare workers: 1. Clinicians and nurses who have been engaged in medical care in the endocrine field for ≥5 years; 2. Who hold a Bachelor's degree or above and have an intermediate or above professional title. Exclusion Criteria: * Patients with T2DM: 1. Who have acute complications of T2DM or other serious life-threatening diseases that preclude cooperation with the study; 2. Who have cognitive impairment or are unable to communicate in writing or verbally Healthcare workers: 1. Who do not have direct contact with patients; 2. Who are currently undergoing standardized training or refresher programs.

Inclusion Criteria: * 1\. Women diagnosed with triple-negative breast cancer by pathology or cytology. 2. Age ≥19 and ≤70 years. 3. ECOG performance status 0-1. 4. Stage II-III breast cancer confirmed pathologically or clinically. 5. Planned to receive AC chemotherapy following paclitaxel/carboplatin as neoadjuvant therapy. 6\. Adequate organ function: 1. Absolute neutrophil count (ANC) ≥1,000 cells/mm³ 2. Platelet count ≥75,000 cells/mm³ 3. Creatinine clearance ≥50 mL/min or serum creatinine \<1.5× ULN 4. Total bilirubin ≤1.5× ULN 5. AST ≤2.5× ULN 6. ALT ≤2.5× ULN 7. Ability to provide written informed consent and willingness to comply with study procedures. Exclusion Criteria: * 1\. Prior treatment with cytotoxic chemotherapy. 2. Prior treatment with G-CSF or pegylated G-CSF. 3. History of conditions that may affect bone marrow function (e.g., severe liver or kidney disease). 4\. Receipt of radiotherapy within 4 weeks prior to study initiation. 5. Active uncontrolled infection or inflammatory disease that may affect study outcomes. 6\. Receipt of blood transfusion within 60 days prior to study initiation. 7. Pregnant, breastfeeding, or unwilling to use appropriate contraception. 8. Any condition judged by the investigator to make the patient unsuitable for participation.

Inclusion Criteria: * Aged ≥18 years * Capable of providing informed consent and completing the questionnaire independently. Exclusion Criteria: * Individuals with serious chronic diseases, immune disorders, or severe psychiatric/cognitive conditions.

Inclusion Criteria: * Patients * Aged ≥65 years old * CLTI * Active symptoms of anxiety or depression (clinician concern) * Carers o In a non-paid caring role for a patient aged ≥65 years with CLTI and active symptoms of anxiety or depression * Staff o Healthcare professional (vascular surgeons, therapists, clinical nurse specialists, geriatricians, anaesthetists, pharmacists) providing care for people aged ≥65 years with CLTI Exclusion Criteria: * Patients * Palliative - death anticipated within one month * Clinical and research team identify as lacking capacity to participate * Carers o Clinical and research team identify as lacking capacity to participate * Staff o Not providing care for older people with CLTI

Inclusion Criteria: * participants will be included in the study if they are patients at the study site * score a 10 to 20 on the PHQ-9 (moderate to moderately severe) * can follow the self-help program, which requires reading materials in English and documenting/tracking work between meetings with a provider Exclusion Criteria: * score greater than 10 on the GAD-7 * PCMHI ineligible (i.e., in specialty mental health) * currently enrolled in a VA or non-VA psychotherapy that would interfere with the study intervention * participants will also be excluded if demonstrating high risk of suicidal ideation/behavior based on the C-SSRS * cognitive impairment conditions that may interfere with the ability to complete the program * conditions that threaten safety (e.g., uncontrolled psychosis, mania/bipolar, moderate to severe substance use disorders)

Inclusion Criteria: * Adults 18 years or older * Record of two blood pressure readings of SBP\>130 on two separate occasions (days) within the past 3 months Exclusion Criteria: * Person is receiving dialysis * Person has had a heart or kidney transplant * Person is pregnant

Inclusion Criteria: * Age ≥ 19 years at the time of inclusion; * Histologically confirmed diagnosis of HER2-positive invasive breast cancer (IHC 3+ score or HER2 amplification by FISH/CISH/SISH); * Decision to initiate treatment with a pertuzumab biosimilar in the neoadjuvant setting (neoadjuvant cohort) or as first-line therapy in the metastatic setting (metastatic cohort), in accordance with local indications; * Treatment prescribed as part of routine clinical care (outside of a clinical trial); * Patient informed and having provided written informed consent. Exclusion Criteria: * Treatment with pertuzumab in a therapeutic setting other than neoadjuvant or first-line metastatic (e.g., adjuvant, late recurrence beyond first-line, maintenance therapy alone, etc.); * Treatment administered as part of an interventional clinical trial; * History of severe allergy or known contraindication to pertuzumab; * Medical records unavailable or inability to ensure at least 6 months of minimal follow-up.

Eligibility Criteria Inclusion Criteria: * Women with only a visual impairment (congenital or acquired) * Able to communicate, speak, and understand Turkish * Voluntarily agree to participate in the study * Over the age of 40 * Have had previous sexual intercourse (Pap smear screening requires sexual activity) Exclusion Criteria: * Diagnosed with breast or cervical cancer * Under the age of 40 * Have not had sexual intercourse before * Have undergone screening for at least one of these two cancer types (breast or cervical) within the last year According to the Turkish Ministry of Health, General Directorate of Public Health, in current screenings conducted in our country, within the breast cancer screening program for women, mammography is recommended every two years for women aged 40-69, and within the cervical cancer screening program, Pap smear and HPV-DNA tests are recommended every five years for women aged 30-65. Since women will be referred by the researchers to KETEM centers after training to undergo mammography and Pap smear screening tests, visually impaired women over the age of 40 who have previously had sexual intercourse will be included in the study, as these two screening tests are performed in this common age group and Pap smear screening requires being sexually active.

Inclusion Criteria: * Using radiographs, intraoral periapical radiographs (RVG) primary endodontic infection will be selected. * Multirooted teeth , root with periapical lesion will be selected * Type 2 diabetics between the ages of 25 years and 60 years will be chosen; both male and female patients * A fasting blood sugar level of 126 mg/dl and a random blood sugar level of less than 200 mg/dl * HbA1c (glycated haemoglobin) ≥ 6.5% Exclusion Criteria: * Patients with systemic conditions other than type 2 diabetes * Women who are pregnant * Those patients that have used antibiotics within the previous three months, * Those patients that have teeth with developmental defects, calcified canals, * Teeth that cannot be isolated with rubber dams, * Tortuous canals * Roots that are fractured

Key Inclusion Criteria 1. Participant's age at the time of signing the informed consent: * United States: 18 to 75 years (inclusive) 2. Diagnosed with type 2 diabetes mellitus (T2DM) with HbA1c ≥7.0% and ≤10.0% at screening 3. Treated with diet and exercise alone or on a stable dose of metformin (≥1000 mg/day) for at least 3 months prior to screening 4. BMI ≥25 kg/m² and ≤50 kg/m² 5. Body weight change \<5% over the past 3 months prior to screening 6. Capable of giving signed informed consent and willing to comply with all protocol procedures Key Exclusion Criteria 1. Type 1 diabetes mellitus or use of glucose-lowering medications other than metformin within 3 months prior to screening 2. Poor glycemic control (fasting plasma glucose \>270 mg/dL) 3. History of diabetic ketoacidosis or severe hypoglycemia within 6 months 4. Clinically significant cardiovascular disease (e.g., NYHA class III/IV heart failure, recent myocardial infarction, stroke, or revascularization within 3 months) 5. History of pancreatitis or factors increasing the risk of pancreatitis 6. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 7. Clinically significant liver disease, renal impairment (eGFR \<60 mL/min/1.73 m²), or abnormal laboratory findings at screening 8. Participation in another investigational study within 30 days or within 5 half-lives of the investigational product, whichever is longer; for GLP-1 receptor agonist-related or weight loss studies, participation within 3 months prior to screening

Inclusion Criteria: 1. Age ≥ 18 years. 2. Patients planning to start or within the first four weeks of treatment with anti-PD-1 immune checkpoint inhibitor therapy either alone or in combination with chemotherapy for curative intent for a known cancer diagnosis (use of immunotherapy must be FDA-approved and not experimental). 3. Life expectancy of at least 12 months per the discretion of the treating physician. Exclusion Criteria: 1. Patients ineligible for anti-PD-1 therapy. 2. Patients with metastatic disease. 3. Patients planning treatment with dual immune checkpoint inhibitor therapy. 4. Bony fractures in the pelvis, bilateral hips/femurs, thoracic spine, or lumbar spine. 5. Known osteoporosis or osteopenia. 6. Planned or previous treatment with denosumab, zoledronic acid, or other bisphosphonate therapy in the last six months. 7. Parathyroid gland disorders, rheumatoid arthritis (unless well-controlled off active biologic therapy without chronic steroid use), CKD stage IV/V, or ESRD. 8. Inability to comply with study procedures. 9. Inability to lie flat for 20-25 minutes during an imaging session. 10. Pregnant or breastfeeding patients. 11. Medical or psychiatric co-morbidities that, in the opinion of the treating physician, would prevent the patient from successfully participating in the study.

Inclusion Criteria: 1. Ages 2-17 years (with caregiver) 2. Patient at BCH AND 3. Underlying cardiovascular risk condition: 1. High Blood Pressure 2. Dyslipidemia 3. Elevated BMI AND 4. Enrolled in or eligible for a Medicaid Healthcare plan OR 5. SNAP eligible Exclusion Criteria: 1\. Conditions that require urgent treatment: 1. Hypertensive Urgency 2. Hypertensive Emergency 3. Dialysis-dependent kidney disease

Inclusion Criteria: * Aged \>/= 18 to 85 years of age * Diagnosis of Combined pre-/post-capillary PH (CPH) defined as mean pulmonary artery pressure \>20mmHg, pulmonary capillary wedge pressure \>15mmHg, and pulmonary vascular resistance ³3 Wood units * NYHA Class I - III * A qualifying Baseline RHC performed within 2 years of consent Clinical echocardiogram within the prior year with LVEF\>/= 45% * Stable PH-specific and/or HF medication regimen and ≤1 diuretic adjustment within the three months prior to enrollment. * Ambulatory - able to perform the walk test Exclusion Criteria: * Pulmonary hypertension due to congenital heart disease, connective tissue disease, or heritable pulmonary arterial hypertension * Prohibited from regular activity due to wheelchair bound status, bed-bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other conditions that limit activity * Pregnancy * Drug and toxin-associated PAH patients with active drug use * Prior or active diagnosis of cirrhosis * Active Malignancy * Patients with evidence of moderate to severe hepatic impairment, defined as Child-Pugh Class B or C, or with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 3 times the upper limit of normal (ULN), should be excluded * eGFR by MDRD \<30mL/mi * FEV1\< 60% predicted with more than mild abnormalities on lung imaging Current enrollment in or completion of any other investigational product study within 30 days of Screening. * Hospitalization for any indication within 30 days of Day 1. * History of severe allergic or anaphylactic reaction or hypersensitivity to NR * No known mutation in NDUFB7